# X-396 Capsule in Advanced NSCLC Patients With ROS1 Gene Rearrangement

> **NCT03608007** · PHASE2 · UNKNOWN · sponsor: **Betta Pharmaceuticals Co., Ltd.** · enrollment: 69 (estimated)

## Conditions studied

- Lung Cancer
- ROS1 Gene Rearrangement

## Interventions

- **DRUG:** X-396 Capsule

## Key facts

- **NCT ID:** NCT03608007
- **Lead sponsor:** Betta Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-06-15
- **Primary completion:** 2020-03
- **Final completion:** 2020-09
- **Target enrollment:** 69 (ESTIMATED)
- **Last updated:** 2020-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03608007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03608007, "X-396 Capsule in Advanced NSCLC Patients With ROS1 Gene Rearrangement". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03608007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*